Home News & Events Events Workshops Workshops Page tools Share Share Share on FacebookShare on XShare on LinkedinShare on Bluesky Print Search Email Accessibility In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related information: Webpage Webinars Webpage Industry Events What’s happening in ICON ICON Plc Attending #OCTSoutheast 10-11 March? Stop by booth \#37 to learn how we support biotechs with flexible clinical development, operational expertise and data‑driven decision‑making. https://lnkd.in/ehPmQF\_H 13h View post View webpage ICON Plc From feasibility to activation, study start-up delays can erode momentum and inflate costs. ICON’s Brian Mallon offers perspective and outlines practical fixes, including AI-driven contracting, early site engagement, and... 14h View post View webpage ICON Plc Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a... 16h View post View webpage ICON Plc ICON has participated in 193 neurodegenerative and neuromuscular studies, enrolling 18,200+ patients at 4,800+ sites globally. Meet our experts at #ADPD2026, booth \#29 to learn how we can support your neurodegeneration ... 18h View post View webpage ICON Plc The type of immunosuppressive treatment a patient with a rare autoimmune condition receives may impact how they respond to vaccines. Read our new article to explore this and other factors that can help determine the best... 9 Mar View post View webpage ICON Plc Only one day until #OCT Southeast begins. ICON will be on site 10–11 March, ready to connect with biotechs looking to strengthen clinical delivery. Visit Booth \#37 to meet our team and discuss how our expertise supports... 9 Mar View post View webpage ICON Plc Meet the ICON team at Medidata NEXT New York. Our specialists will be available throughout the event to discuss how ICON is supporting sponsors to improve study build quality, streamline delivery and adopt technology wit... 9 Mar View post View webpage ICON Plc A multi phase ICON supported study details the leading symptoms in advanced/metastatic HCC including fatigue, weight loss, weakness, appetite loss, and sleep disturbance. Findings show wide ranging effects on daily fun... 9 Mar View post View webpage ICON Plc ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle... 8 Mar View post View webpage ICON Plc Join Steve Hunt at Medidata NEXT New York for a roundtable discussion on real world lessons from early adopters of Medidata Designer. Steve will share what effective adoption looks like in practice, where ICON teams are ... 6 Mar View post View webpage ICON Plc The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon... 6 Mar View post View webpage ICON Plc Last week, our teams across ICON came together to recognise Rare Disease Day and raise awareness for the millions of people and families living with rare conditions. Colleagues took part in activities including creating... 6 Mar View post
